The 2018 Antibody-based Therapeutics and BioProduction Forum

The Antibody and Antibody-based Therapeutics have entered the center stage of drug discovery. Roughly, as of end of 2017, over 70 antibody therapeutics have been approved. Not only in Western Countries, there have been also considerable biologics R&D, manufacturing and commercial activities in Asia. In 2015, the China FDA has also released the country's first biosimilar guidelines to establish the basic principles for development and technical evaluation of biosimilars towards the adoption of a more concrete and well-defined regulatory pathway to further promote the industry. In return, the 2018 Antibody-based Therapeutics and BioProduction Forumis to build up and facilitate the communication and partnerships to accelerate Biologics R&D, Characterization and Production.

Forum Main Sessions

Antibody-based Therapeutics Forum
Recent Trends and Development for Antibody Therapeutics
The Development of Antibody Therapeutics in China 
Antibody-Drug Conjugates Development and Production
Bispecific and Novel/Similar Antibody Therapeutics Development
Innovative Platform for Antibody Discovery
Biological Characterization Strategies
 

Biological Production Forum

Innovation in Biological Manufacturing
Integrated Strategies for Rapid, Low-cost Clinical Material Production
Quality Control, cGMP Manufacturing and Externalizaton
Biologics Formulation, Aggregation and Stability Stuides
Cell Line, Culture Engineering and Downstream Processing
Continuous Processing, QbD/PAT and Single-use Systems

Currently we are receiving the podium and poster abstracts. If you are working in the above areas, you are invited to submit a proposal. Please contact the committee for the up-to-date agenda.